Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for Prevention of Radial Artery Occlusion Post-Transradial Access
NCT03630055Phase 3Terminated
- Sponsor
- University of Ottawa Heart Institute
- Start
- Oct 2018
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in Radial artery occlusion (RAO) comparing Rivaroxaban with Standard of Care (2 arms). Primary endpoints: Rate of radial artery occlusion at 30 days and International Society on Thrombosis and Haemostasis definition of major bleeding at 30 days. Started Oct 2018; status: terminated.
02
Drugs
rivaroxaban
03
Conditions
Radial artery occlusion (RAO)
Beyond the preview
Go deeper on NCT03630055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630055.